Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

Dr. Reshma Jagsi discusses optimizing breast cancer care by safely de-escalating surgery and radiation using patient-centered communication

Dr. Sara Nunnery and Dr. Neil Iyengar discuss metabolic health, GLP-1s and prescribing exercise to improve outcomes for breast cancer survivors.

Following her breast cancer diagnosis, Guerdy Abraira utilized genomic testing to gain clarity on her treatment path.

The 49th Annual Miami Breast Cancer Conference recently hosted a cornerstone event for the advocacy community: the CURE Educated Patient® Breast Cancer Summit.

Drs. Nunnery and McCann discuss the evolving HER2-positive breast cancer treatment paradigm in the latest episode of “Breast Cancer Briefing.”

Jonise S. Louis shares her journey of navigating a metastatic breast cancer diagnosis and chemotherapy while pregnant with the help of her oncology team.

Dr. Hope Rugo and advocate Jonise Louis discuss new ADCs, biomarker testing, and patient-centered dosing for metastatic triple-negative breast cancer.

Metastatic breast cancer survivor Casey Liening shares her adoption story in a candid interview.

Shondia McFadden-Sabari of Bold and Breastless shares how intuition and early detection saved her life during a dual breast cancer diagnosis.

Dr. Don S. Dizon presented information on pregnancy with a breast cancer diagnosis and what patients should know.

Dr. Anastasia Tousimis explores the feasibility, risks and surgical techniques for performing NSM in radiated patients to ensure oncologic safety.

During the Miami Breast Cancer Conference, CURE discussed ADCs with Dr. Kevin Kalinsky.

Dr. Kevin Kalinsky discusses common side effects associated with the FDA-approved combination of Enhertu and Perjeta for breast cancer.

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for patients with TNBC.

Clinical trial data show a carboplatin-free regimen offers similar results with fewer side effects for patients with stage 2 to 3 HER2+ disease.

Zovegalisib plus Faslodex elicited responses in patients with HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer.

Here are five key takeaways regarding the use of GLP-1 receptor agonists in patients who are undergoing breast cancer treatment.

At the Miami Breast Cancer Conference, Dr. Heather A. Parsons shared growing evidence for the prognostic value of circulating tumor DNA.

New data show that Enhertu had similar safety in the real world as in clinical trials in patients with HER2-low metastatic breast cancer.

A community study finds Enhertu effective for HER2-low mBC, with over half of patients seeing tumor shrinkage and high one-year survival rates.

New data show more women over 70 are safely skipping sentinel lymph node biopsies for HR+ breast cancer, reducing unnecessary surgery and risks.

Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the potential for improved outcomes.

Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.

Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according to Dr. Kevin Kalinsky.

Gene expression testing helps determine chemotherapy needs for HR+ breast cancer, optimizing treatment and reducing unnecessary toxicity.

Genetic and genomic testing guide breast cancer risk assessment and treatment, as discussed by Dr. Mark Robson at the Miami Breast Cancer Summit.

Dr. Debu Tripathy discusses recent research on the use of circulating tumor DNA in metastatic breast cancer care.